Cancer: A Very Short Introduction

About this book

In 1961 John F. Kennedy pledged to put a man on the moon by the end of the decade. Nine years later, Neil Armstrong and Buzz Aldrin walked on the moon. Ten years later, Richard Nixon echoed this pledge by declaring a 'war' on cancer. More than 30 years later, however, cancer remains one of the largest causes of death worldwide, with around 1 in 3 developing the disease. Curing cancer is not 'rocket science', but the question is, why has cancer proved to be harder to tackle than the moon landings turned out to be?

Cancer research is a major economic activity. There are constant improvements in treatment techniques that result in better cure rates and increased quality and quantity of life for those with the disease, yet stories of breakthroughs in a cure for cancer are often in the media.

In this Very Short Introduction Nick James, founder of the CancerHelp UK website, examines the trends in diagnosis and treatment of the disease, as well as its economic consequences. Asking what cancer is and what causes it, he considers issues surrounding expensive drug development, what can be done to reduce the risk of developing cancer, and the use of complementary and alternative therapies.

Contents

1. The size of the cancer problem
2. How does cancer develop?
3. How is cancer treated?
4. Cancer research
5. The costs of cancer care
6. Alternative and complementary approaches to cancer care
7. The future shape of cancer care

Customer Reviews

Biography

Professor Nicholas James is Professor and Deputy Dean at The Institute of Cancer Research and The Royal Marsden Hospital. He is a world-leading researcher on advanced prostate and bladder cancer. He has recently chaired a Commission on Prostate Cancer for the leading medical journal The Lancet. James co-founded one of the oldest patient information websites in 1994, which became the main patient resource on the Cancer Research UK website. Most recently he set up the Man Van project, aimed at improving outcomes in men at high risk of late diagnosis of prostate cancer.